Share price rebounding from yesterday's inexplicable selloff. Very little resistance to $21 and beyond. Seems like one or more investors were making a portfolio adjustment yesterday or short sellers were trying to grab some cheap shares. In any event, if T is approved in early 2019, the share price should explode. And, SELB is not a meaningful threat to K, especially with new clinical Phase 2 MIRROR study combining pegloticase with methotrexate to address immunological issues. Methotrexate is the most common immunomodulator used by rheumatologists GTLA.